Marcus Thibodeau

FDA's tighter grip on competitive pharma ads now scrutinizes overall tone and presentation.

Synchronized promotional and label strategies unlock the biggest gains from indication expansions.

Payers want real-world evidence but lack the expertise and frameworks to evaluate it fairly.

Health plans expect manufacturers to submit evidence following AMCP's standard dossier format.

Pharma-DTx deals multiply compliance complexity as regulatory gaps widen.

Brands must treat paid patient testimonials as drug claims subject to full safety disclosure.

Effective design and targeted support can close the gaps where patients abandon their medications.

Pharma field teams waste 77% of approved content due to compliance delays and poor feedback loops.

Modular content frameworks cut drug launch timelines by pre-approving reusable components.

Granular system setup, not slow reviewers, determines if MLR clears in days or weeks.

Parallel MLR review cuts cycle time when coordination scaffolding gets built first.

Successful drug launches in crowded markets depend on sequencing, not marketing.

Field reps and digital channels excel at different things; deploy both strategically.